Status:

COMPLETED

LIFE Study: Least Invasive Fast-Track EVAR

Lead Sponsor:

TriVascular, Inc.

Conditions:

Abdominal Aortic Aneurysm

Eligibility:

All Genders

18+ years

Brief Summary

The primary objectives of the LIFE Study are to demonstrate the clinical and cost benefits associated with using the Ovation® Abdominal Stent Graft Platform under the least invasive conditions defined...

Detailed Description

The LIFE Study is a prospective, consecutively enrolling, non-randomized multi center post-market registry to evaluate the ultra low profile (14F) Ovation Abdominal Stent Graft Platform when using in ...

Eligibility Criteria

Inclusion

  • Patient is ≥ 18 years of age.
  • Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study).
  • Patient has signed an IRB approved informed consent form.
  • Patient is considered by the treating physician to be a candidate for elective open surgical repair of the AAA.
  • Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following: abdominal aortic aneurysm \>5.0 cm in diameter, aneurysm has increased in size by 0.5 cm in last 6 months, or maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment.
  • Patient has suitable anatomy that allows use of the TriVascular Ovation® Abdominal Stent Graft Platform.
  • Patient has suitable femoral arteries at the percutaneous access site that allow use of the Perclose ProGlide Suture-Mediated Closure System via the pre-close technique.
  • Patient must be willing to comply with all required follow-up exams.

Exclusion

  • Patient has a need for emergent surgery.
  • Patient has a dissecting aneurysm.
  • Patient has an acutely ruptured aneurysm.
  • Patient has an acute vascular injury.
  • Patient has had a previous repair of the abdominal aortic aneurysm or the iliac artery.
  • Patient has a mycotic aneurysm or has an active systemic infection.
  • Patient has unstable angina.
  • Patient has unstable peripheral artery disease with critical limb ischemia.
  • Patient has congestive heart failure.
  • Patient has had a myocardial infarction and/or stroke within the past 3 months.
  • Patient requires use of techniques that would cover the renal arteries.
  • Patient requires planned adjunctive devices to complete the procedure.
  • Patient has a major surgical or interventional procedure planned during or within ±30 days of the AAA repair.
  • Patient has history of connective tissue disease.
  • Patient has history of bleeding disorders or refuses blood transfusions.
  • Patient has dialysis dependent renal failure or baseline serum creatinine level \>2.0mg/dl.
  • Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.
  • Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE), PEG-based polymers, fluorinated ethylene propylene (FEP) or nitinol.
  • Patient is on home oxygen.
  • Patient is morbidly obese (BMI ≥40 kg/m2).
  • Patient was admitted from a skilled nursing facility.
  • Patient has a limited life expectancy of less than 1 year.
  • Patient has an inability to be discharged within 1 day of the procedure.
  • Patient is currently participating in an investigational device or drug clinical trial.
  • Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.

Key Trial Info

Start Date :

September 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 1 2016

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT02224794

Start Date

September 1 2014

End Date

June 1 2016

Last Update

June 8 2021

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Abrazo Arizona Heart Hospital

Phoenix, Arizona, United States, 85006

2

St. Luke's Episcopal Hospital

Houston, Texas, United States, 77030